Skip to content

US · PRLD · BIOTECHNOLOGY

Prelude Therapeutics Incorporated (PRLD) intrinsic value and stock valuation

$3.23as of 2026-11-21 · Mkt cap 258.47M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Prelude Therapeutics Incorporated DCF and intrinsic value

InvestorsCraft values PRLD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PRLD’s statements →

Prelude Therapeutics Incorporated Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Wilmington, DE 19805 preludetx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$12.1M
20182025
Net income
-$-99.5M
20182025
Free cash flow
-$-56.37M
20182025
Total equity
$68.6M-20.2% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$12.1M$7M$0.00$0.00$0.00
Operating income-$-104.57M-$-139.71M-$-132.28M-$-123.54M-$-113.73M
Net income-$-99.5M-$-127.17M-$-121.83M-$-115.44M-$-111.69M
EPSd-$-1.29M-$-1.68M-$-2.02M-$-2.44M-$-2.35M
Operating cash flow-$-56.3M-$-102.89M-$-107.06M-$-83.73M-$-83.53M
Capital expenditure-$-70K-$-760K-$-3.51M-$-3.02M-$-2.32M
Free cash flow-$-56.37M-$-103.65M-$-110.58M-$-86.75M-$-85.85M
Total assets$141.3M$175.5M$277.7M$220.5M$305.1M
Total debt$17.8M$18M$16.9M$1.83M$1.74M
Net debt-$-17.47M$5.55M-$-8.4M-$-28.77M-$-30.09M
Total equity$68.6M$131.5M$237.1M$195.4M$285.9M
Cash and short-term investments$103.2M$133.6M$232.9M$201.7M$291.2M
Income statement
20252024202320222021
Revenue$12.1M$7M$0.00$0.00$0.00
Cost of revenue$1.71M$0.00$0.00$0.00$0.00
Gross profit$10.4M$7M$0.00$0.00$0.00
Research and development expenses$94.3M$118M$103.4M$92.9M$86.8M
Selling, general and administrative expenses$22.4M$28.7M$28.9M$30.7M$27M
Other expenses-$-1.71M$0.00-$0.00$0.00$0.00
Operating expenses$115M$146.7M$132.3M$123.5M$113.7M
Cost and expenses$116.7M$146.7M$132.3M$123.5M$113.7M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.71M$1.77M$1.17M$1.32M$920K
Ebitda-$-97.79M-$-125.4M-$-120.66M-$-114.11M-$-110.78M
Operating income-$-104.57M-$-139.71M-$-132.28M-$-123.54M-$-113.73M
Total other income/expenses, net$5.07M$12.5M$10.4M$8.1M$2.04M
Income before tax-$-99.5M-$-127.17M-$-121.83M-$-115.44M-$-111.69M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-99.5M-$-127.17M-$-121.83M-$-115.44M-$-111.69M
Weighted average shares outstanding$77M$75.8M$60.4M$47.4M$47.6M
Weighted average diluted shares outstanding$77M$75.8M$60.4M$47.4M$47.6M
Balance sheet
20252024202320222021
Cash and short-term investments$103.2M$133.6M$232.9M$201.7M$291.2M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$105.7M$135.9M$235.6M$204.4M$295.1M
Property, plant and equipment, net$32.3M$35.5M$37.7M$6.7M$5.64M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$35.6M$39.6M$42.1M$16.1M$9.98M
Total assets$141.3M$175.5M$277.7M$220.5M$305.1M
Accounts payable$3.98M$7.73M$4.58M$6.78M$7.84M
Short-term debt$2.74M$2.7M$1.48M$1.83M$1.74M
Deferred revenue$33.7M$0.00$0.00$0.00$0.00
Total current liabilities$53M$25.6M$21.8M$21.7M$19.2M
Long-term debt$15M$15.3M$15.4M$0.00$0.00
Deferred revenue, non-current$1.8M$0.00$0.00$0.00$0.00
Total non-current liabilities$19.7M$18.4M$18.8M$3.36M$0.00
Capital lease obligations$17.8M$18M$16.9M$1.83M$1.74M
Total liabilities$72.7M$44.1M$40.6M$25.1M$19.2M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-683.06M-$-583.56M-$-456.39M-$-334.56M-$-219.12M
Accumulated other comprehensive income (loss)$10K$40K$220K-$-1.69M-$-710K
Total equity$68.6M$131.5M$237.1M$195.4M$285.9M
Total investments$68M$121.1M$207.6M$171.1M$259.4M
Total debt$17.8M$18M$16.9M$1.83M$1.74M
Net debt-$-17.47M$5.55M-$-8.4M-$-28.77M-$-30.09M
Cash flow statement
20252024202320222021
Net income-$-99.5M-$-127.17M-$-121.83M-$-115.44M-$-111.69M
Depreciation and amortization$1.34M$1.77M$1.17M$1.32M$920K
Stock-based compensation$11.9M$21.3M$25.6M$25.1M$20.9M
Change in working capital$28.4M$4.22M-$-10.48M$930K$3.62M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-3.92M$3.31M-$-2.27M-$-350K$3.9M
Net cash provided by operating activities-$-56.3M-$-102.89M-$-107.06M-$-83.73M-$-83.53M
Investments in property, plant and equipment-$-70K-$-760K-$-3.51M-$-3.02M-$-2.32M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$53.5M$90.2M-$-34.65M$81.7M-$-263.8M
Common stock issued$25M$330K$135.7M$810K$161.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$24.8M-$-120K$136.4M$810K$164.9M
Net change in cash$22M-$-12.82M-$-5.31M-$-1.22M-$-182.44M
Cash at end of period$38.5M$16.5M$29.3M$34.7M$35.9M
Operating cash flow-$-56.3M-$-102.89M-$-107.06M-$-83.73M-$-83.53M
Capital expenditure-$-70K-$-760K-$-3.51M-$-3.02M-$-2.32M
Free cash flow-$-56.37M-$-103.65M-$-110.58M-$-86.75M-$-85.85M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Prelude Therapeutics Incorporated

        Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.

        CEO
        Krishna Vaddi
        Employees
        79
        Beta
        0.95

        Explore

        Frequently asked questions

        What is the intrinsic value of Prelude Therapeutics Incorporated (PRLD)?

        InvestorsCraft does not currently publish an intrinsic value for PRLD. How the IC value is calculated.

        Is PRLD undervalued?

        InvestorsCraft does not publish an undervaluation signal for PRLD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.